Author

Pilar Varela

EFFECTIVENESS AND SAFETY OF SWITCHING FROM ADALIMUMAB REFERENCE TO BIOSIMILAR IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE: THE ADA-SWITCH STUDY
EFFECTIVENESS AND SAFETY OF SWITCHING FROM ADALIMUMAB REFERENCE TO BIOSIMILAR IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE: THE ADA-SWITCH STUDY

Pilar Varela  et al.

BISMUTH QUADRUPLE REGIMEN WITH TETRACYCLINE OR DOXYCYCLINE VERSUS PYLERA® AS THIRD-LINE RESCUE THERAPY FOR H. PYLORI INFECTION: A PROSPECTIVE MULTICENTER ANALYSIS OF THE EUROPEAN REGISTRY ON HELICOBACTER PYLORI MANAGEMENT (HP-EUREG)
BISMUTH QUADRUPLE REGIMEN WITH TETRACYCLINE OR DOXYCYCLINE VERSUS PYLERA® AS THIRD-LINE RESCUE THERAPY FOR H. PYLORI INFECTION: A PROSPECTIVE MULTICENTER ANALYSIS OF THE EUROPEAN REGISTRY ON HELICOBACTER PYLORI MANAGEMENT (HP-EUREG)

Pilar Varela  et al.

MANAGEMENT AND OUTCOME OF POSTOPERATIVE CROHN’S DISEASE IN THE ELDERLY AS COMPARED TO YOUNG ADULTS: DATA FROM ENEIDA REGISTRY
MANAGEMENT AND OUTCOME OF POSTOPERATIVE CROHN’S DISEASE IN THE ELDERLY AS COMPARED TO YOUNG ADULTS: DATA FROM ENEIDA REGISTRY

Pilar Varela  et al.

EFFECTIVENESS AND SAFETY OF USTEKINUMAB (UST) IN PATIENTS WITH ACTIVE CROHN'S DISEASE (CD) IN REAL LIFE: SUSTAIN STUDY
EFFECTIVENESS AND SAFETY OF USTEKINUMAB (UST) IN PATIENTS WITH ACTIVE CROHN'S DISEASE (CD) IN REAL LIFE: SUSTAIN STUDY

Pilar Varela  et al.

LONG-TERM DURABILITY AND SAFETY OF USTEKINUMAB (UST) IN PATIENTS WITH ACTIVE CROHN'S DISEASE (CD) IN REAL LIFE: SUSTAIN STUDY
LONG-TERM DURABILITY AND SAFETY OF USTEKINUMAB (UST) IN PATIENTS WITH ACTIVE CROHN'S DISEASE (CD) IN REAL LIFE: SUSTAIN STUDY

Pilar Varela  et al.

Item 1 - 5 / 5
1